The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

The study, first of the three late-stage trials, was testing the drug, navacaprant, in patients with major depressive ...

Key Takeaways Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

If you or a loved one is struggling with anxiety or depression, contact the Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline at 800-662-4357 for information on ...

Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials ...

Even the coroner specified that the self-inflicted death was an “adverse effect” of the antidepressant the man had been ...

This paper reviews recent findings on the pharmacogenetics of antidepressant drugs and future clinical applications. Ultimately, these studies should lead to the use of genetic testing to guide ...

New York, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Overview: The Antidepressant Drugs Market size is expected to reach USD 20.1 billion by 2024 and is further anticipated to reach USD 26.9 billion by ...